PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
1.43%
Revenue growth 50-75% of Medical - Pharmaceuticals median of 2.62%. Guy Spier would scrutinize if slower growth is temporary.
1.93%
Cost growth 50-90% of Medical - Pharmaceuticals median of 3.81%. Mohnish Pabrai would examine sustainable cost advantages.
-0.51%
Gross profit decline while Medical - Pharmaceuticals median is 1.98%. Seth Klarman would investigate competitive position.
-1.92%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.83%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-0.94%
Operating expenses reduction while Medical - Pharmaceuticals median is 2.71%. Seth Klarman would investigate advantages.
1.45%
Total costs growth below 50% of Medical - Pharmaceuticals median of 3.79%. Joel Greenblatt would investigate efficiency.
-6.25%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
1.00%
D&A growth 50-90% of Medical - Pharmaceuticals median of 1.19%. Mohnish Pabrai would examine asset strategy.
-4.69%
EBITDA decline while Medical - Pharmaceuticals median is 4.01%. Seth Klarman would investigate causes.
-6.04%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.18%. Seth Klarman would investigate causes.
1.06%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 0.30%. Joel Greenblatt would investigate advantages.
-0.37%
Operating margin decline while Medical - Pharmaceuticals median is 1.19%. Seth Klarman would investigate causes.
693.01%
Other expenses growth while Medical - Pharmaceuticals reduces costs. Peter Lynch would examine differences.
51.54%
Pre-tax income growth exceeding 1.5x Medical - Pharmaceuticals median of 3.23%. Joel Greenblatt would investigate advantages.
49.40%
Margin change of 49.40% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
49.60%
Tax expense change of 49.60% versus flat Medical - Pharmaceuticals. Walter Schloss would verify strategy.
52.44%
Net income growth exceeding 1.5x Medical - Pharmaceuticals median of 2.84%. Joel Greenblatt would investigate advantages.
50.28%
Margin change of 50.28% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
52.44%
EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 5.44%. Joel Greenblatt would investigate advantages.
52.44%
Diluted EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 5.48%. Joel Greenblatt would investigate advantages.
0.00%
Share count reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.25%. Joel Greenblatt would investigate strategy.
0.00%
Diluted share reduction exceeding 1.5x Medical - Pharmaceuticals median of 0.22%. Joel Greenblatt would investigate strategy.